Singapore's August Global Partners invests in Gene Solutions
Singapore's August Global Partners invests in Gene Solutions
Singapore-headquartered August Global Partners is investing in genomic testing company Gene Solutions through a proprietary funding round.
|
Gene Solutions and August Global Partners announced the signing of an MoU on January 9.
August Global Partners will assist Gene Solutions in enhancing the performance of their oncology solutions by providing access to world-class research resources and regional partners. This will enable Gene Solutions to further validate its test accuracy and implement the DNAsphere.AI suite in personalised cancer treatment applications.
Gene Solutions will support broader adoption of precision medicine and targeted therapeutics in Asia through the development of a suite of AI technologies that encompass a scientific knowledge base, large language models, multi-omics insights, and clinical database to push the boundaries of next-generation sequencing services.
The AI suite, named DNAsphere.AI, was developed by Gene Solutions through years of clinical research partnerships and DNA testing expertise across both reproductive health and oncology verticals. With this AI suite, Gene Solutions can reduce sequencing costs while significantly improving test performance, consequently increasing the accessibility of personalised solutions.
Nguyen Hoai Nghia, CEO and chairman of Gene Solutions, said, "Cancer is a debilitating disease that has impacted many of our loved ones or ourselves profoundly. This partnership is a pivotal milestone in our company’s mission to provide advanced and accessible oncology solutions. By combining our genomic expertise with AGP’s investment and network, we aim to make blood-based cancer screening and treatment monitoring tests more accurate and more affordable."
Basil Lui, founding partner of August Global Partners, said, "Genomic technologies can revolutionise cancer management via earlier detection and personalised treatment insights, and Gene Solutions is an emerging leader in providing affordable high-quality tests. As more tests are delivered and validated, Gene Solutions can further build competitive advantage from the AI flywheel effect. Our investment underscores our commitment to visionary entrepreneurs and innovation-led healthcare solutions."
Gene Solutions is now expanding its product portfolio in personalised cancer care to the global market. This includes their renowned early cancer detection and cancer monitoring tests. More recently, the company announced the launch of single-cancer early detection tests developed with AI-driven ctDNA technology, aimed at improving early cancer screening adherence in asymptomatic populations. Gene Solutions also has ongoing programmes with biopharma leaders to co-develop novel cancer therapeutics, such as targeted cancer drugs, neoantigen vaccines, and cell therapies.
